Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence

Linda D Simmler, Rebecca Wandeler and Matthias E Liechti

Abstract

**Background:** Methamphetamine-abuse is a worldwide health problem for which no effective therapy is available. Inhibition of methamphetamine-induced transporter-mediated dopamine (DA) release could be a useful approach to treat methamphetamine-addiction. We assessed the potencies of bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone (MDPV) to block DA uptake or to inhibit methamphetamine-induced DA release in HEK-293 cells expressing the human DA transporter.

**Findings:** Bupropion, methylphenidate, and MDPV inhibited methamphetamine-induced DA release with relative potencies corresponding to their potencies to block DA uptake (potency ranks: MDPV > methylphenidate > bupropion).

**Conclusions:** Bupropion and methylphenidate antagonize the effects of methamphetamine in vitro and may be potential candidates for the treatment of stimulant addiction. However, drugs that very potently antagonize the effect of methamphetamine are likely to also exhibit considerable abuse liability (MDPV > methylphenidate > bupropion).

**Keywords:** Methamphetamine, Addiction, Dopamine, Dopamine transporter, Bupropion, Methylphenidate, MDPV

Findings

**Background**

Methamphetamine dependence is a major public health problem. Currently, no medical treatments are approved for stimulant dependence indicating the need to explore potential candidates [1]. Methamphetamine releases dopamine (DA) via the DA transporter (DAT) [2,3]. DA is thought to mediate the reinforcing effects of psychostimulants, which lead to drug dependence [4,5]. Blocking the pronounced release of DA by methamphetamine may therefore be an interesting therapeutic option for the treatment of methamphetamine dependence [1]. Bupropion and methylphenidate are DA uptake inhibitors that interact with the same pharmacological target as methamphetamine [6-11]. Bupropion is used as an antidepressant and smoking cessation aid [7,9]. Methylphenidate is effectively used in the treatment of attention-deficit/hyperactivity disorder [12,13]. In addition, small clinical studies indicated promising beneficial effects for both medications in methamphetamine dependence [1]. Bupropion reduced the acute subjective effects of methamphetamine in a laboratory study [14] and methamphetamine use in dependent patients with moderate drug use [15-18]. Methylphenidate reduced amphetamine use in dependent patients [19] and it is now being investigated in methamphetamine-addiction (clinicaltrials.gov: NCT01044238). Bupropion also reduced methamphetamine self-administration in rats [20] or rhesus...
monkeys [21]. In contrast, methylphenidate did not affect methamphetamine self-administration in rhesus monkeys [21].

The precise pharmacological mechanism of action of bupropion and methylphenidate with regard to their therapeutic effects in methamphetamine dependent patients is not known. Dopamine is thought to contribute to the drug-high and euphoria produced by psychostimulants and mediates the addictive properties of drugs of abuse [4,22]. Amphetamines reverse the transport of DA through the DAT and this effect is thought to play a key role in the addictive potential of amphetamines [5]. The DA uptake inhibitors bupropion and methylphenidate may therefore prevent methamphetamine from interacting with the DAT to release DA, and such an effect would antagonize effects of methamphetamine. Several DA uptake inhibitors have previously been shown to prevent DAT-mediated release of DA by amphetamines in vitro. For example, bupropion and methylphenidate [23] as well as GBR12909 [3] inhibited DAT-mediated amphetamine- or methamphetamine induced DA release from rat synaptosomes. In HEK-293 cells expressing human DAT, methylphenidate inhibited DA efflux induced by methamphetamine [24]. These and similar data suggest that bupropion and methylphenidate block the interaction of methamphetamine with the DAT to release DA and thereby act as antagonists of amphetamine-like drugs.

The aim of the present study was to test and compare the effects of bupropion and methylphenidate on methamphetamine-induced DA efflux in HEK-293 cells expressing human DAT in vitro. Bupropion and methylphenidate were selected because of their availability as licensed medications and the clinical data described above. We also included 3,4-methylenedioxypyrovalerone (MDPV) into the study because it has been shown to be a very potent DAT inhibitor [10,25].

We hypothesized that 1) the DA uptake blockers would prevent methamphetamine-induced DA release and 2) the potencies of the drugs to inhibit methamphetamine-induced DA release would correspond to their potencies to block DA uptake.

Methods

Drugs

(±)-Bupropion hydrochloride was from Toronto Research Chemicals (North York, Canada), d-methamphetamine, (±)-methylphenidate, and (±)-MDPV were supplied as hydrochloride salts by Lipomed (Arlesheim, Switzerland).

Inhibition of DA uptake

The potencies of the drugs to inhibit the DAT were evaluated as previously described [26] in HEK-293 cells (Invitrogen, Zug, Switzerland) stably transfected with the human DAT [8].

Inhibition of methamphetamine-induced DA release

We performed DA transporter mediated release experiments as previously published [25] with slight modification. In brief, HEK-293 cells expressing the human DAT as stated above were cultured in 48 well-plates. Cells were filled with 3H-DA, washed, and incubated with 250 μL buffer containing the drug alone or in combinations. Drug combinations were 10 μM of methamphetamine with bupropion, methylphenidate, or MDPV in different concentrations. DA release was stopped after 15 min by removing the release buffer from the cells. To quantify the DA release we determined the radioactivity in the cells after another wash step. The residual radioactivity in the cells after methamphetamine alone defined 100% DA release. Baseline (0% release) was defined as the radioactivity remaining in the cells treated with bupropion, methylphenidate, or MDPV alone at the highest concentration used.

Results

Inhibition of DA uptake

Bupropion, methylphenidate, and MDPV inhibited the uptake of DA. MDPV was the most potent DAT inhibitor followed by methylphenidate and bupropion. Methamphetamine blocked DA uptake with similar potency to bupropion (Figure 1).

Inhibition of methamphetamine-induced DA release

Methamphetamine released DA with a potency (EC50) of 1.56 μM (0.9 μM-2.8 μM, 95% CI) as shown previously [25]. DA release induced with 10 μM methamphetamine was inhibited concentration-dependently by bupropion, methylphenidate, and MDPV (Figure 2). MDPV was the most potent inhibitor of the methamphetamine-induced DA release followed by methylphenidate and bupropion (Figure 2). The IC50 values are shown in Table 1. The potencies (IC50 values) of the drugs to block DA release correlated highly with the IC50 values of the drugs to block DA uptake (Figure 3) as confirmed by a correlation coefficient of >0.99, p < 0.05.
Values are means of 3–4 independent experiments and 95% confidence intervals (CI).

Table 1 Potencies of drugs to block DA uptake or methamphetamine-induced DA release

| DA uptake inhibitor | Methamphetamine-induced DA release |
|---------------------|------------------------------------|
|                     | IC_{50} (μM) (95% CI)              | IC_{50} (μM) (95% CI)               |
| Methamphetamine     | 1.05 (0.7-1.5)                     | 14.2 (9.7-21)                      |
| Bupropion           | 1.76 (1.1-2.8)                     | 14.2 (9.7-21)                      |
| Methylphenidate     | 0.14 (0.1-0.2)                     | 1.67 (0.7-4.0)                     |
| MDPV                | 0.031 (0.03-0.04)                  | 0.28 (0.1-0.6)                     |

Discussion

In the present study, the DA uptake inhibitor bupropion inhibited DA release induced by methamphetamine. This mechanism might underlie the reduction in the methamphetamine-induced subjective drug high by bupropion pretreatment documented in a clinical laboratory study [14] and the reduced methamphetamine consumption in drug users treated with bupropion [15-18]. Methylphenidate also blocked the methamphetamine-induced DA release similar to bupropion and this effect may also antagonize the rewarding effects of methamphetamine and its use in dependent patients. In fact, methylphenidate showed beneficial effects in amphetamine dependent patients [19] and is being investigated for the treatment of methamphetamine addiction (clinicaltrials.gov: NCT01044238). Thus, inhibition of DA release might be a pharmacological mechanism how DA uptake inhibitors reduced the subjective stimulant drug effects or drug consumption in the clinical studies noted above. In addition, methylphenidate and bupropion also increase DA levels and therefore both drugs may also act as substitution treatments for methamphetamine use. In the present study we also included the very potent DA uptake inhibitor MDPV to explore how the potency of a drug as DA uptake inhibitor relates to its potency to antagonize the pharmacological effect of methamphetamine. MDPV blocked methamphetamine-induced DA release with high potency reflecting its high potency as an uptake inhibitor. We found that the potencies of the drugs to block methamphetamine-induced DA release correlated closely and significantly with their potencies to act as DA uptake inhibitors. The finding suggests that the more potent a drug antagonizes the DA release produced by methamphetamine the more potent it also blocks DA uptake. This finding may have important clinical implications regarding the abuse liability of potential antagonist treatments for methamphetamine dependence. With regard to the drugs tested in the present study, the antidepressant bupropion is a low-potency DA transporter inhibitor and it is considered a drug that does not produce relevant euphoria nor addiction [27,28]. Methylphenidate is an intermediate-potency DA transporter inhibitor and is known to produce euphoria at higher doses [29,30] and to have a relevant abuse potential [31,32]. The cathinone MDPV is a high-potency DA transporter inhibitor and street designer drug (“super coke”, “research chemical”, “bath salt”) with high addiction potential similar to the DA releaser methamphetamine [25,33-35]. Our findings indicate that drugs that potentely and effectively antagonize the effect of methamphetamine are likely to exhibit high abuse liability themselves because they block DA uptake. In fact, the potency of amphetamine-type stimulants to block DA uptake has been shown to correlate with the doses used by humans [25]. Furthermore, potent DA transport uptake inhibition is sufficient to produce addiction because cocaine and MDPV only block DA uptake and do not induce DA release as methamphetamine [5,25]. It is therefore questionable whether there are any compounds that do not activate the
DA system and lack abuse liability but effectively prevent methamphetamine from interacting with DAT. On the other hand, abuse liability of medications can be reduced by using extended-release drug formulations.

Methamphetamine also has additional effects on the DA system (e.g., on monoamine oxidase and the vesicular monoamine transporter), which were not studied here. These effects of methamphetamine take place within the cells and are likely prevented by DAT inhibitors [36] that block methamphetamine transport into the cell. Methamphetamine also releases norepinephrine [2,3] and norepinephrine is thought to contribute to the acute effects of amphetamine-type drugs [3,37-39]. MDPV [25] and methylphenidate [6,40], and to a lower extent bupropion [7,11], block the norepinephrine transporter and these drugs could also block methamphetamine-induced norepinephrine release. We did not address potential drug interactions at the norepinephrine transporter because in contrast to DA, norepinephrine is not generally thought to be a major mediator of the addictive properties of psychostimulants. However, interactions at the norepinephrine transporter could be expected to contribute to any therapeutic effects of the drugs tested in the present study. Finally, it should be noted that we assessed only a small number of DAT inhibitors. However, the drugs were selected to cover a wide range of DAT inhibition potencies including also the very potent DAT inhibitor MDPV.

Conclusion
Our in vitro studies and the limited clinical data indicate that the low- and intermediate-potency DA uptake inhibitors bupropion and methylphenidate may be potential candidates as treatments of amphetamine-type stimulant dependence [1] due to their property to inhibit methamphetamine-induced DA efflux. Their clinical efficacy needs further confirmation.

Availability of supporting data
The data supporting the results of this article are included within the article. This work was supported by the Swiss National Science Foundation (grant no. 32323B_144996). Publication costs are supported by the Neurex network (www.neurex.org).

Abbreviations
DA: Dopamine; DAT: Dopamine transporter; MDPV: 3,4-methylenedioxyamphetamine.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
LDS and MEL designed this study and wrote the manuscript. RW and LDS performed the experiments. All authors analyzed the data. All authors have read and approved the final manuscript.

References
1. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Bathe SL: Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 2010, 69(6):578–592.
2. Estherman AJ, Henningsen RA, Neve KA, Janowsky A: Release of dopamine via the human transporter. Mol Pharmacol 1994, 45(2):312–316.
3. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FJ, Pantilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39(1):32–41.
4. Wise RA: Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 2008, 14(2–3):169–183.
5. Suber D: How addictive drugs disrupt presynaptic dopamine neurotransmission. Neurology 2011, 69(6):628–649.
6. Han DD, Gu HH: Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006, 6:6.
7. Stahl SM, Pradiko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S: A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary care companion to the Journal of clinical psychiatry 2004, 6(4):159–166.
8. Tatsuru M, Goshan K, Bkalery KD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340(2–3):249–258.
9. Dvoskin LP, Rauhut AS, King-Prospis KA, Bardo MT: Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006, 12(3):176–207.
10. Weltzin PC, Butler D, Deschamps JF, Mackas BK: 1-[(4-Methylphenyl)-2-pyrrolidin-1-yl]-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 2006, 49(14):1240–1342.
11. Carroll FJ, Muresan AZ, Blough BE, Navarro HA, Mascarella SW, Eaton JB, Huang X, Damaj MI, Lukas RJ: Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine. J Med Chem 2011, 54(1):1441–1448.
12. Schachter HM, Pham B, King J, Langford S, Moher D: How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001, 165(11):1475–1488.
13. Vitelli B: Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. CMAJ 2001, 165(11):1505–1506.
14. Newton TF, Roache JD, De La Garza R 2nd, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kainh R: Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006, 31(7):1537–1544.
15. Shoport S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, De La Garza R, Newton T, Ling W: Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008, 96(3):222–232.
16. Brensilver M, Heinzreiling KG, Swanson AN, Shoport SJ: A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/ augmentation. Drug Alcohol Depend 2012, 125(1-2):169–72.
17. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kainh R, Vesic F, Ling W, et al: Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008, 33(5):1162–1170.
18. McCann DJ, Li SH: A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther 2012, 18(5):414–418.
19. Tihonen J, Kuoppi-Kallio K, Furu I, Tuomola P, Kukkannio O, Varna H, Sokero P, Hakki J, Merinok K: A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007, 164(1):160–162.
20. Reichel CM, Murray JE, Grant KM, Bevis RA: Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend 2009, 100(1):215–224.
21. Schindler CW, Gilman JP, Pandillo LV, McCann DJ, Goldberg SR: Comparison of the effects of methamphetamine, bupropion, and methylphenidate
on the self-administration of methamphetamine by rhesus monkeys. Exp Clin Psychopharmacol 2011, 19(1):11–10.

22. Koob GF, Volkow ND: Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35(1):217–238.

23. Gruner JA, Marcy VR, Lin YQ, Bozyca-Coyne D, Marino MJ, Gasior M: The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep 2009, 32(11):1432–1438.

24. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM: Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther 2007, 321(1):116–137.

25. Simmler LD, Buser TA, Dorzelli M, Schramm Y, Dieu LH, Huwyler J, Chabaz S, Hoener MC, Liechti ME: Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013, 168:458–470.

26. Hysek CM, Simmler LD, Nicola V, Vischer N, Dorzelli M, Krähenbühl S, Grouzmann E, Hoener MC, Liechti ME: Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One 2012, 7:e36476.

27. Stern WC, Hanto-Truxa N, Rogers J, Miller L: Clinical profile of the novel antidepressant bupropion. Adv Biochem Psychopharmacol 1982, 32:21–34.

28. Rothman RB: High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 1991, 46(20):PL17–21.

29. Martin WR, Sloan J, Sapira JD, Jasinski DR: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phentramine, and methylphenidate in man. Clin Pharmacol Ther 1971, 12(2):245–258.

30. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey S, Ashby C, Liebermann J, Hitzemann R, et al: Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995, 52(6):456–463.

31. Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK: Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology 2009, 204(1):73–83.

32. Hysek CM, MacDonald EK, Rush CR: Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001, 68(3):611–627.

33. Spiller HA, Ryan ML, Weston RG, Jansen J: Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Tox 2011, 49(8):499–505.

34. Coppola M, Mondola R: 3,4-methylenedioxypropyvalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 2012, 208(1):12–15.

35. Wattron LB, Kufahl PR, Nemirovsky NE, Sewalka K, Olive MF: Potent reinforcing effects of the synthetic cathinone methylenedioxypropyvalerone (MDPV) in rats. Neuropsychopharmacology 2011, 36:5440.

36. Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pfitz C: Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J Neurochem 1998, 71(3):1289–1297.

37. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME: The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther 2011, 90(2):246–255.

38. Newton TF: A perhaps unexpected role of norepinephrine in actions of MDMA. Clin Pharmacol Ther 2011, 90(2):215–216.

39. Sofuoglu M, Sewell RA: Norepinephrine and stimulant addiction. Addict Biol 2009, 14(2):119–129.

40. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS: Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010, 68(9):854–860.

Cite this article as: Simmler et al.: Bupropion, methylphenidate, and 3,4-methylenedioxypropyvalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Research Notes 2013 6:220.